Shares of Wockhardt Ltd rose 3.5% to touch a day’s high of Rs 1,854 on 14th July, after the company announced its exit from the US generics business as part of a broader realignment.

Wockhardt has exited its loss-making US generics business, filing for voluntary liquidation under Chapter 7 of the US Bankruptcy Code.

The move aligns with Wockhardt’s long‑term vision to become a differentiated, innovation‑led pharma company.

In the future, the company will focus on two pillars: new antibiotic drug discovery and its biologics portfolio in insulin.

US generics posted an $8 million loss in FY25, and a strategic review found the segment misaligned with Wockhardt’s innovation agenda.

The exit affects two wholly‑owned US subsidiaries—Morton Grove Pharma and Wockhardt USA LLC—effective from 11th July, 2025.

Shedding the generics arm has freed up capital and management bandwidth to invest in higher‑growth, innovation‑driven segments.

At 3:30 PM, the shares of Wockhardt Ltd closed 3.35% higher at Rs 1,816 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!